AgomAb Therapeutics NV (AGMB) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ProKidney is the larger company by market cap ($662.6 million vs $454.1 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | PROK |
|---|---|---|
| Share price | $9.22 | $1.66 |
| Market cap | $454.07M | $662.64M |
| 1-day change | +4.77% | +5.73% |
| YTD return | — | -25.89% |
| 1-year return | — | -49.08% |
| 5-year return | — | -83.18% |
| EPS (TTM) | $-2.08 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $3.48 |
| 52-week low | $7.97 | $1.30 |
| Distance from 52-week high | -48.26% | -52.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +308.57% | +276.51% |
| Average volume | 139.21K | 1.30M |
| Shares outstanding | 49.25M | 208.93M |
| Employees | 62 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
AGMB vs PROK FAQ
Which is bigger, AgomAb Therapeutics NV or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $662.64M compared with $454.07M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.